华领医药宣布成功完成在中国香港开展的SENSITIZE研究
Nov 30, 2024 19:58 HKT |  |
|
NEFECON(R) Included in National Reimbursement Drug List (NRDL)
Nov 29, 2024 10:48 HKT | |
|
耐賦康(R)納入新版國家醫保藥品目錄
Nov 29, 2024 10:45 HKT | |
|
耐赋康(R)纳入新版国家医保药品目录
Nov 29, 2024 10:42 HKT | |
|
「依拉環素臨床應用綜合評價項目」終期報告發佈
Nov 26, 2024 11:11 HKT | |
|
'依拉环素临床应用综合评价项目'终期报告发布
Nov 26, 2024 11:04 HKT | |
|
Everest Medicines Announces NEFECON(R)'s Full Approval in South Korea
Nov 19, 2024 17:37 HKT | |
|
雲頂新耀宣佈耐賦康(R)在韓國獲批 商業化進程再創里程碑
Nov 19, 2024 17:28 HKT | |
|
云顶新耀宣布耐赋康(R)在韩国获批 商业化进程再创里程碑
Nov 19, 2024 17:10 HKT | |
|
雲頂新耀宣佈耐賦康(R)Ⅲ期試驗開放標籤第二療程擴展研究積極結果
Nov 11, 2024 12:23 HKT | |
|
云顶新耀宣布耐赋康(R)Ⅲ期试验开放标签第二疗程扩展研究积极结果
Nov 11, 2024 12:15 HKT | |
|
Everest Medicines Announces the Launch of VELSIPITY(R) in the Guangdong-Hong Kong-Macau Greater Bay Area
Oct 25, 2024 11:28 HKT | |
|
雲頂新耀宣佈伊曲莫德（VELSIPITY(R)）獲批進入粵港澳大灣區 為潰瘍性結腸炎患者帶來新選擇
Oct 25, 2024 11:20 HKT | |
|
云顶新耀宣布伊曲莫德（VELSIPITY）获批进入粤港澳大湾区 为溃疡性结肠炎患者带来新选择
Oct 25, 2024 11:20 HKT | |
|
Founder of Hua Medicine Dr. Chen Li was awarded the 'C.C. Tan Life Science Industrialization Award'
Oct 25, 2024 09:18 HKT | |
|
HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLD's The Liver Meeting 2024
Oct 25, 2024 08:57 HKT |  |
|
T.MAN Pharmaceutical PCL (SET: TMAN) Showcases Leadership in Health Innovation, Aiming for Sustainable Growth Following Listing on SET
Oct 23, 2024 09:00 HKT |  |
|
Everest Medicines Announces Positive Results of Complete Chinese Subpopulation Data from the NEFECON Global Phase 3 NefIgArd Clinical Trial
Oct 22, 2024 11:52 HKT | |
|
雲頂新耀宣佈耐賦康®NefIgArd III期全球臨床試驗完整中國亞組資料的積極結果
Oct 22, 2024 11:43 HKT | |
|
云顶新耀宣布耐赋康(R) NefIgArd III期全球临床试验完整中国亚组数据的积极结果
Oct 22, 2024 11:37 HKT | |
|